Exact Sciences (EXAS)

• Market cap: $9.98B
• 1 day: 8.84%
• 5 days: 7.32%
• 1 month: -22.39%
• 3 months: -8.56%
• 6 months: 5.73%
• Year to date: -26.91%
• 1 year: -19.87%
• 5 years: -35.66%
• 10 years: 138.48%
• Sector: Healthcare
• Industry: Medical Laboratories

About: Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Employees: 6,600

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

125% more funds holding in top 10

Funds holding in top 10: 4 [Q2] → 9 (+5) [Q3]

69% more first-time investments, than exits

New positions opened: 118 | Existing positions closed: 70

63% more capital invested

Capital invested by funds: $7.62B [Q2] → $12.4B (+$4.77B) [Q3]

15% more call options, than puts

Call options by funds: $194M | Put options by funds: $169M

9% more funds holding

Funds holding: 529 [Q2] → 577 (+48) [Q3]

0.87% more ownership

Funds ownership: 97.68% [Q2] → 98.55% (+0.87%) [Q3]

15% less repeat investments, than reductions

Existing positions increased: 164 | Existing positions reduced: 194

Research analyst outlook

18 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $60 11% upside
• Avg. target: $75 39% upside
• High target: $95 76% upside

18 analyst ratings

• positive: 18 100%
• neutral: 0 0%
• negative: 0 0%

Piper Sandler David Westenberg 45% 1-year accuracy 9 / 20 met price target	39% upside $75	Overweight Maintained	11 Nov 2024
Citigroup Patrick Donnelly 31% 1-year accuracy 11 / 35 met price target	39% upside $75	Buy Maintained	6 Nov 2024
Jefferies Brandon Couillard 23% 1-year accuracy 3 / 13 met price target	58% upside $85	Buy Maintained	6 Nov 2024
Stifel Daniel Arias 6% 1-year accuracy 1 / 18 met price target	24% upside $67	Buy Maintained	6 Nov 2024
BTIG Mark Massaro 54% 1-year accuracy 13 / 24 met price target	21% upside $65	Buy Maintained	6 Nov 2024